Companies: 10,795·Total market cap: $144.5T
Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc.

GLUENASDAQHealthcare● Active
$17.00
+$0.63(+3.85%)
Market Cap$1.1B
P/E Ratio—
52W High$25.77
52W Low$4.12
SEC Filings

Monte Rosa Therapeutics, Inc. (GLUE) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001826457 · GLUE · NASDAQ · as of Jun 8, 2026

Filing snapshot

360
Total Filings
4
Latest Form
2026-06-02
Most Recent
2021
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001826457 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2026-03-17
Fiscal Year End
Mar 17, 2026
Accession No.
0001193125-26-109360
Primary Document
glue-20251231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001826457 · Accession 0001193125-26-109360

Latest Key Filings

10-QQuarterly Report
10-Q
2026-05-07
View 10-Q on SEC
8-KCurrent Report
8-K
2026-05-07Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-05-15
View
10-QQuarterly Report
10-Q
2026-05-07
View
8-KCurrent Report
8-K
2026-05-07
View
ARSARS
ARS
2026-04-29
View
DEFA14AProxy Statement (Additional)
DEFA14A
2026-04-29
View
DEF 14AProxy Statement
DEF 14A
2026-04-29
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-04-22
View
3Initial Statement of Beneficial Ownership
3
2026-04-07
View
SCHEDULE 13D/ASCHEDULE 13D/A
SCHEDULE 13D/A
2026-03-19
View
S-8Employee Stock Plan Registration
S-8
2026-03-17
View
10-KAnnual Report
10-K
2026-03-17
View
8-KCurrent Report
8-K
2026-03-17
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2026-02-17
View
Showing 1–15 of 221 filingsForm 4 / 144 hidden· 360 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001826457  |  Exchange: NASDAQ · Healthcare

Monte Rosa Therapeutics, Inc. (NASDAQ: GLUE) has submitted 360 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2021. As a Healthcare sector company with CIK 0001826457, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Monte Rosa Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Monte Rosa Therapeutics, Inc. 10-K was filed on 2026-03-17 for fiscal year ending 2026. Historical GLUE 10-K annual reports are available from 2020 through 2026.

Investors researching Monte Rosa Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-08
Related Companies SEC Filings — Healthcare
DAWN SEC Filings →VIR SEC Filings →AVBP SEC Filings →MGTX SEC Filings →TBPH SEC Filings →REPL SEC Filings →GERN SEC Filings →DNA SEC Filings →
→ GLUE Financials→ GLUE Earnings→ GLUE Insider Trades

Frequently Asked Questions

GLUE SEC Filings · 8 questions

Monte Rosa Therapeutics, Inc. (GLUE) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 360 filings and access original documents at no cost. Monte Rosa Therapeutics, Inc.'s CIK is 0001826457.

GLUE SEC filingsMonte Rosa Therapeutics, Inc. SEC documentsfind GLUE 10-K